Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.57%
#2 Palladium Network Palladium Network +6.43%
#3 Cryptopia Cryptopia +4.36%
#4 SIXSEVEN SIXSEVEN +4.11%
#5 GRVT Token GRVT Token +3.87%
#6 Kinetiq Kinetiq +3.41%
#7 Test Test +3.32%
#8 Movement Movement +3.31%
#9 Victoria VR Victoria VR +3.17%
#10 Jito Jito +3.05%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
EFFECTOR Therapeutics, Inc. EFFECTOR Therapeutics, Inc.

EFFECTOR Therapeutics, Inc.

EFTRW
Rang in Aktien #42260
eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the... eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective translation regulator inhibitors aimed at combating cancer. Their primary investigational drug, Tomivosertib, is an orally administered small-molecule MNK inhibitor currently undergoing Phase 2b clinical trials. This candidate is being evaluated for its efficacy in patients suffering from metastatic non-small cell lung cancer. Additionally, the company is advancing zotatifin, another small molecule engineered to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 1/2 clinical studies for individuals with various solid tumors. Furthermore, it's being tested in a Phase 2a open-label expansion cohort, in conjunction with fulvestrant and abemaciclib, for patients afflicted with ER-positive breast cancer. eFFECTOR Therapeutics, Inc. also holds a research collaboration and licensing pact with Pfizer Inc., focused on co-developing eIF4E inhibitors. Established in 2012, the company maintains its corporate headquarters in Solana Beach, California.
Aktienkurs
$0.0006
Zuletzt synchronisiert: 2025-11-25
Marktkapitalisierung
$2.82K
Veränderung (1 Tag)
59,900.00%
Veränderung (1 Jahr)
59,900.00%
Land
US
Handel EFFECTOR Therapeutics, Inc. (EFTRW)

Kategorie

Healthcare
Gewinn für EFFECTOR Therapeutics, Inc. (EFTRW)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von EFFECTOR Therapeutics, Inc. betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von EFFECTOR Therapeutics, Inc. von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR